|
Dow Jones Business News Geron Shares Rise on Liver-Cell Research Results Tuesday April 1, 12:00 pm ET MENLO PARK, Calif. -- Shares of Geron Corp. got a boost Tuesday after the biopharmaceutical company said it can produce basic functional cells of the liver from human embryonic stem cells. Geron said that a reliable producer of liver cells, or hepatocytes, would be useful in drug research and for transplantation therapy for patients suffering from liver failure. ADVERTISEMENT The ability to cultivate hepatocytes would be useful to researchers, because current methods by which subjects are tested for toxicity and metabolic effects are considered inadequate, the company said. Researchers currently use rats and mice in these types of tests and such models only approximate human metabolism. The wide availability of standardized adult hepatocytes would allow drug studies to be performed earlier in the discovery process, the company said. Shares of Geron were up $1.63, or 31%, to $6.92 in midday trading on the Nasdaq Stock Market (News - Websites). In March, Geron shares jumped after the company said its experimental cancer vaccine killed a variety of tumor-cell types in laboratory cultures. The Wall Street Journal reported that Geron has reported intriguing results from its basic research programs several times over the past few years, often fueling a surge in its stock. On most such occasions, however, the share price has fallen back as investors digested the fact that practical applications remained years away. -Paul Welitzkin; Dow Jones Newswires; 609-520-7260 |
|
| aus der Diskussion: | Geron mit Hammernews!! |
| Autor (Datum des Eintrages): | siam123 (01.04.03 19:10:05) |
| Beitrag: | 59 von 3,090 (ID:9052135) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |